Monday, September 27, 2021
12:00 p.m. to 1:00 p.m.
Virtual

Register Here

On September 9, 2021, the Department of Health and Human Services (HHS) announced an amendment to the COVID-19 Public Readiness and Emergency Preparedness (PREP) Act declaration to allow licensed pharmacists, pharmacy interns, and pharmacy technicians to order and administer select COVID-19 therapeutics, including subcutaneous monoclonal antibodies.  Join us on Monday, September 27, 2021, at 11:00 a.m. for the COVID-19 Monoclonal Antibody Assessment & Administration Webinar.

The U.S. Food and Drug Administration has issued several Emergency Use Authorizations for the use of anti-SARS-CoV-2 monoclonal antibodies – bamlanivimab/etesevimab, casirivimab/imdevimab, and sotrovimab. Licensed pharmacists are now authorized to both order and administer monoclonal antibodies as COVID-19 therapeutics. We’ll review the clinical evaluation of indications and contraindications for COVID-19 therapeutics, adverse events, as well as and product-specific requirements or considerations related to FDA approval, authorization, clearance, or licensing of COVID-19 therapeutics. This training program is designed to fully satisfy the requirements of the PREP Act by supplementing APhA’s Pharmacy-based Immunization Delivery certificate training program.

Note: Zoom link will be emailed to ALL registered attendees on the morning of the 27th

Learning Objectives

At the completion of this activity, the participant will be able to:

• Describe the indications for treatment and post-exposure prophylaxis of COVID-19 using monoclonal antibodies
• Compare and contrast the treatment data of REGEN-COV, Sotrovimab, and Bamlanivimab/Etesevimab
• Explain provider payment key facts for monoclonal antibody therapy
• Apply treatment and post-exposure prophylaxis criteria to patient cases

Speaker

Brooke Rossheim, MD, MPH
Virginia Department of Health

Registration Rates

VPhA Member: $10
Non-Member: $20